We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-15.2%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$783M
AUM Growth
-$209M
Cap. Flow
+$1.16M
Cap. Flow %
0.15%
Top 10 Hldgs %
67.03%
Holding
48
New
4
Increased
3
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.4M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$12.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10M
4
DBVT
DBV Technologies
DBVT
+$4.35M
5
GLMD icon
Galmed Pharmaceuticals
GLMD
+$1.16M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.52M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.23M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.36M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.05M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.45M

Sector Composition

Rank Sector Weight
1 Healthcare 97.51%
2 Materials 2.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
26
Aurinia Pharmaceuticals
AUPH
$1.93B
$8.28M 1.06%
1,213,290
– –
SLNO
27
DELISTED
Soleno Therapeutics
SLNO
$7.46M 0.95%
290,646
– –
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$6.1B
$7.44M 0.95%
264,878
– –
CBAY
29
DELISTED
Cymabay Therapeutics
CBAY
$7.13M 0.91%
906,000
– –
GLMD icon
30
Galmed Pharmaceuticals
GLMD
$4.95M
$6.63M 0.85%
5,396
+665
+14% +$1.16M
KALA icon
31
KALA BIO
KALA
$13.6M
$5.1M 0.65%
418
– –
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$3.83M 0.49%
105,000
– –
SRRA
33
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.22M 0.41%
60,957
– –
ARVN icon
34
Arvinas
ARVN
$536M
$2.69M 0.34%
209,666
-90,334
-30% -$1.43M
GNCA
35
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.35M 0.3%
1,022,500
– –
ZLAB icon
36
Zai Lab
ZLAB
$2.06B
$1.9M 0.24%
81,819
-149,191
-65% -$2.77M
TMBR
37
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$1.74M 0.22%
1,075
– –
DBVT
38
DBV Technologies
DBVT
$817M
$1.73M 0.22%
+27,000
New +$4.35M
RNAC icon
39
Cartesian Therapeutics
RNAC
$227M
$1.45M 0.19%
18,202
-7,173
-28% -$1.64M
AGRX
40
DELISTED
Agile Therapeutics
AGRX
$872K 0.11%
757
– –
TRVN
41
DELISTED
Trevena, Inc.
TRVN
$743K 0.09%
2,765
– –
FOMX
42
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$723K 0.09%
201,478
-226,022
-53% -$983K
AKTX
43
Akari Therapeutics
AKTX
$14M
$543K 0.07%
432
– –
VIRX
44
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$81K 0.01%
5,585
– –
SLNOW
45
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$19K ﹤0.01%
188,772
– –
DCPH
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-212,648
Closed -$8.23M
ONCT
47
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-750
Closed -$165K
SBBP
48
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-918,132
Closed -$4.45M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Vivo Capital held 48 positions worth $783M, down 21% from $992M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Vivo Capital's Q4 2018 filing shows 4 new, 3 increased, 8 reduced and 3 closed positions. Its largest new stake was Iovance Biotherapeutics: 1,600,000 shares worth $14.2M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $8.52M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q4 2018 buy was Iovance Biotherapeutics: 1,600,000 shares worth $14.2M.
  • Vivo Capital added most to Galmed Pharmaceuticals in Q4 2018, an estimated $1.16M increase.
  • Vivo Capital's biggest Q4 2018 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $8.52M.
  • Vivo Capital fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2018, selling an estimated $8.23M.
  • Vivo Capital's ten largest holdings make up 67% of its $783M portfolio in Q4 2018.
  • Vivo Capital opened 4 new positions and closed 3 in Q4 2018.
  • Vivo Capital's portfolio value fell 21% quarter-over-quarter to $783M.

Based on Vivo Capital's 13F filing for Q4 2018, filed 13 Feb 2019.